The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Investigating navtemadlin for the treatment of MPNs: the Phase III POIESIS study
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential impact of navtemadlin on the treatment landscape of myeloproliferative neoplasms (MPNs), noting that it is the first MDM2 inhibitor to proceed to an advanced stage of development in MPNs. The agent is currently being investigated in the Phase III POIESIS study (NCT06479135), which has a unique design outlined by Dr Bose. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
